ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis

June 04, 2025 01:34 AM AEST | By Cision

Google News:

ThinkCyte Unveils MorphoScan Cloud: A Versatile Cloud-Based Platform for AI-Driven Cell Morphology Data Analysis — Image source: Kalkine Media

Recent News

Virgin Galactic stock jumps on SpaceX competition speculation

EMA says Ozempic, Wegovy may cause rare eye condition

Vera Therapeutics stock sinks following competitor’s successful trial

Goldman Sachs lowers Tesla vehicle delivery estimates

TOKYO, June 3, 2025 /PRNewswire/ -- ThinkCyte, a life science company pioneering advanced AI-powered cell analysis and sorting technologies, today announced the pre-commercial launch of MorphoScan Cloud, its new cloud-based platform designed for flexible data access, faster processing, and advanced AI–driven analysis. The launch coincides with the 38th Annual Congress of the International Society for the Advancement of Cytometry (CYTO 2025), held in Denver, Colorado from May 31 to June 4.

MorphoScan Cloud expands the user experience for customers of VisionSort, ThinkCyte's flagship morphometric cell analysis and sorting platform. With secure cloud storage and multi-user access capabilities, MorphoScan Cloud enables research teams across geographies to centralize, share, and analyze VisionSort-generated data more efficiently.

With an integrated suite of advanced analytical tools, purpose-built to unlock deeper biological insights from complex cellular data, MorphoScan Cloud is the next step in ThinkCyte's commitment to bringing advanced morphometric profiling hardware and software solutions to life science research. Whether applying supervised or unsupervised learning techniques, users will be able to leverage cloud computing to explore their datasets using advanced algorithms including deep learning.

"With MorphoScan Cloud, we're providing our customers with more than just storage - we're offering an intelligent platform that transforms how research teams engage with cellular data," said Waichiro Katsuda, CEO of ThinkCyte. "By combining the new view of biology provided by VisionSort with the analytical power of AI with the accessibility of the cloud, we aim to streamline data analysis workflows, accelerate discovery, and empower innovation across the life sciences."

Attendees at CYTO 2025 can experience MorphoScan Cloud firsthand at the ThinkCyte booth (#627) or more information, visit https://thinkcyte.com/mkt/morphoscan-cloud/

About ThinkCyte

ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific research platforms based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company developed Ghost Cytometry™, a proprietary AI-based, label-free cell analysis and sorting technology and partners with major global biopharmaceutical companies and leading academic research institutes to drive pioneering research. For more information, please visit www.thinkcyte.com.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.